We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Elanco Animal Health Incorporated | NYSE:ELAN | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.22 | 1.69% | 13.26 | 13.36 | 12.92 | 13.03 | 3,252,780 | 21:37:51 |
From Apr 2023 to Apr 2024
By Mary de Wet
Elanco Animal Health Inc. received conditional approval from the Food and Drug Administration on Monday for its drug Varenzin-CA1 to treat anemia in cats with chronic kidney disease.
The agency said Varenzin-CA1 helps to increase production of erythropoietin in the kidney, which in turn stimulates the bone marrow to produce more red blood cells.
The current treatments available for nonregenerative anemia in cats with CKD include blood transfusion, supplemental iron therapy and erythropoietin replacement, the FDA said.
Under conditional approval, the FDA has concluded that the drug is safe for its intended purpose and has a reasonable expectation of being effective. Cats suffering from the disease can receive the treatment while full effectiveness data is being collected, the agency said.
The initial conditional approval is valid for one year with the potential for four annual renewals, the FDA said.
Write to Mary de Wet at mary.dewet@dowjones.com
(END) Dow Jones Newswires
May 01, 2023 15:32 ET (19:32 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Elanco Animal Health Chart |
1 Month Elanco Animal Health Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
